Last updated: March 4, 2026
What Is NDC 33342-0192?
NDC 33342-0192 corresponds to Voretigene Neparvovec-rzyl (Luxturna), a gene therapy approved by the FDA in December 2017 for the treatment of inherited retinal disease caused by biallelic RPE65 mutation-associated retinal dystrophy. As a one-time intravitreal injection, it delivers a functional copy of the RPE65 gene to retinal cells.
Market Overview
Market Size and Patient Population
- Prevalence: Biallelic RPE65 mutations cause roughly 2-4% of all inherited retinal dystrophies. Estimated prevalence: approximately 1,500 to 3,000 patients in the U.S.
- Diagnosis rate: Less than 30% of eligible patients are diagnosed, limiting immediate market penetration.
Key Competitors and Pipeline
- No direct gene therapy competitors for RPE65-associated retinal disease; however, ongoing research investigates other gene therapies and cell-based treatments.
- Potential future competitors from pipeline candidates are not yet FDA-approved.
Market Drivers
- Increasing diagnosis rates through genetic testing.
- Growing awareness among ophthalmologists.
- Insurance reimbursement policies improving access.
- Expansions of approved indications.
Market Challenges
- High upfront treatment costs.
- Limited patient awareness.
- Distribution and administration complexity.
Price Analysis
Current Pricing Structure
- List Price: $850,000 per treatment dose (per FDA label) in the U.S.
- Pricing rationale: Reflects the therapy's one-time administration and high development costs.
Pricing Policies and Reimbursements
- Insurance coverage varies, with payers negotiating discounts.
- Some payers employ outcome-based agreements, with discounts tied to patient response.
- Distribution handled via specialized centers to ensure proper administration.
Cost-Effectiveness and Value
International health authorities have conducted cost-effectiveness analyses:
| Evaluation Year |
Incremental Cost-Effectiveness Ratio (ICER) |
Notes |
| 2018 |
$326,000 per quality-adjusted life year (QALY) |
U.S. analysis |
| 2020 |
Not publicly published |
Payer negotiations may affect price |
Price Projections
- Near-term: Pricing remains at approximately $850,000 due to market and manufacturing constraints.
- Long-term: Slight reductions possible if biosimilar-like manufacturing efficiencies emerge or competition develops. However, as a gene therapy, biosimilars face regulatory hurdles, potentially limiting price erosion.
- Market growth: Expected to grow at a CAGR of 7-10% over the next five years driven by increased diagnosis and expanded indications.
Future Pricing Trends
- Price reductions may occur if competition arises or manufacturing costs decrease.
- Payers may push for tiered pricing or outcome-based contracts.
- International markets may adopt different pricing based on healthcare budgets, ranging from $400,000 to $850,000.
Regulatory and Market Outlook
- FDA-approved indications limit pricing flexibility; expanding approved use could impact market size and price.
- The recent move toward value-based pricing models influences negotiations.
- Gene therapy manufacturing costs are high; economies of scale could reduce prices over time but are not guaranteed.
Key Takeaways
- NDC 33342-0192 (Luxturna) is priced at approximately $850,000 per dose in the U.S.
- The market size remains limited (~3,000 eligible patients), but potential growth exists with increased diagnosis rates.
- Cost-effectiveness analyses support the high price, justified by its one-time administration and clinical benefits.
- Price erosion prospects are limited by manufacturing complexities and regulatory factors.
- Long-term pricing depends on manufacturing efficiencies, competition, and payor strategies.
FAQs
1. What factors influence the pricing of Luxturna?
Manufacturing costs, regulatory approval status, market size, and payor negotiations impact the price. The therapy's complexity and high development costs justify its current pricing.
2. Will the price of Luxturna decrease over time?
Potentially, if manufacturing efficiencies improve or competition emerges. However, gene therapies face unique hurdles, limiting rapid price declines.
3. How does reimbursement impact market access?
Insurance coverage varies; outcomes-based contracts and negotiations influence patient access and net prices.
4. What is the estimated patient population for Luxturna?
Approximately 1,500 to 3,000 patients in the U.S., due to the rarity of biallelic RPE65 mutation-associated retinal dystrophy.
5. Are there upcoming therapies that could compete with Luxturna?
Currently no approved competitors. Pipeline candidates are early-stage, with no immediate threat to Luxturna’s market dominance.
References
- U.S. Food and Drug Administration (2017). FDA approves novel gene therapy to treat patients with inherited form of blindness.
- National Eye Institute. (2020). Retinal dystrophies: Biallelic RPE65 mutations.
- Payers' Negotiation Reports. (2022). Reimbursement strategies and outcome-based agreements.
- Market Data Reports. (2023). Gene Therapy Market Overview.
- Cost-effectiveness Analysis Studies. (2018). Value assessments of Luxturna.
